Stock Track | ADMA Biologics Soars 5.17% on Analyst's Buy Rating and Growth Prospects

Stock Track03-05

ADMA Biologics Inc. (ADMA) stock surged 5.17% in Wednesday's intraday trading session, driven by positive analyst sentiment and optimism about the company's growth prospects.

Mizuho Securities analyst Anthony Petrone maintained a "Buy" rating on ADMA stock earlier this week, citing the company's transition to a new auditor and growth opportunities. The favorable analyst coverage likely boosted investor confidence, fueling the stock's upward momentum.

ADMA Biologics, a biopharmaceutical company, is focused on developing and commercializing specialty plasma-derived biologics. With a promising product pipeline and strategic initiatives underway, the company appears well-positioned for growth, according to analysts' assessments.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1190328774?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-05 22:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1190328774","market":"us","top_or_hot":-1,"title":"Stock Track | ADMA Biologics Soars 5.17% on Analyst's Buy Rating and Growth Prospects","media":"Stock Track","content":"<p>ADMA Biologics Inc. (ADMA) stock surged 5.17% in Wednesday's intraday trading session, driven by positive analyst sentiment and optimism about the company's growth prospects.</p>\n\n<p>Mizuho Securities analyst Anthony Petrone maintained a \"Buy\" rating on ADMA stock earlier this week, citing the company's transition to a new auditor and growth opportunities. The favorable analyst coverage likely boosted investor confidence, fueling the stock's upward momentum.</p>\n\n<p>ADMA Biologics, a biopharmaceutical company, is focused on developing and commercializing specialty plasma-derived biologics. With a promising product pipeline and strategic initiatives underway, the company appears well-positioned for growth, according to analysts' assessments.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | ADMA Biologics Soars 5.17% on Analyst's Buy Rating and Growth Prospects</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | ADMA Biologics Soars 5.17% on Analyst's Buy Rating and Growth Prospects\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-03-05 22:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ADMA Biologics Inc. (ADMA) stock surged 5.17% in Wednesday's intraday trading session, driven by positive analyst sentiment and optimism about the company's growth prospects.</p>\n\n<p>Mizuho Securities analyst Anthony Petrone maintained a \"Buy\" rating on ADMA stock earlier this week, citing the company's transition to a new auditor and growth opportunities. The favorable analyst coverage likely boosted investor confidence, fueling the stock's upward momentum.</p>\n\n<p>ADMA Biologics, a biopharmaceutical company, is focused on developing and commercializing specialty plasma-derived biologics. With a promising product pipeline and strategic initiatives underway, the company appears well-positioned for growth, according to analysts' assessments.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADMA","symbol_name":"ADMA Biologics Inc","start_time":0,"source_url":"","article_id":"1190328774","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1190328774","pubTimestamp":1741185860,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"ADMA Biologics Inc.  stock surged 5.17% in Wednesday's intraday trading session, driven by positive analyst sentiment and optimism about the company's growth prospects.Mizuho Securities analyst Anthony Petrone maintained a \"Buy\" rating on ADMA stock earlier this week, citing the company's transition to a new auditor and growth opportunities. The favorable analyst coverage likely boosted investor confidence, fueling the stock's upward momentum.ADMA Biologics, a biopharmaceutical company, is focus","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ADMA":"ADMA Biologics Inc"},"translate_title":"股票跟踪ADMA Biologics因分析师买入评级和增长前景而飙升5.17%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADMA":1},"content_text":"ADMA Biologics Inc. (ADMA) stock surged 5.17% in Wednesday's intraday trading session, driven by positive analyst sentiment and optimism about the company's growth prospects.\nMizuho Securities analyst Anthony Petrone maintained a \"Buy\" rating on ADMA stock earlier this week, citing the company's transition to a new auditor and growth opportunities. The favorable analyst coverage likely boosted investor confidence, fueling the stock's upward momentum.\nADMA Biologics, a biopharmaceutical company, is focused on developing and commercializing specialty plasma-derived biologics. With a promising product pipeline and strategic initiatives underway, the company appears well-positioned for growth, according to analysts' assessments.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1190328774"}